Skip to Content

Vericel Corp VCEL

Morningstar Rating
$47.32 −0.99 (2.05%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

VCEL is trading at a 21% premium.
Price
$47.19
Fair Value
$66.97
Uncertainty
High
1-Star Price
$51.19
5-Star Price
$59.99
Economic Moat
Lxyb
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if VCEL is a good fit for your portfolio.

Trading Information

Previous Close Price
$48.31
Day Range
$47.2048.61
52-Week Range
$27.9250.09
Bid/Ask
$32.95 / $54.99
Market Cap
$2.26 Bil
Volume/Avg
284,291 / 479,654

Key Statistics

Price/Earnings (Normalized)
139.11
Price/Sales
12.19
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in advanced therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
305

Comparables

Valuation

Metric
VCEL
LYEL
PTGX
Price/Earnings (Normalized)
139.11
Price/Book Value
11.100.645.32
Price/Sales
12.199.15
Price/Cash Flow
70.39
Price/Earnings
VCEL
LYEL
PTGX

Financial Strength

Metric
VCEL
LYEL
PTGX
Quick Ratio
4.0416.4111.51
Current Ratio
5.1816.7411.66
Interest Coverage
−19.69
Quick Ratio
VCEL
LYEL
PTGX

Profitability

Metric
VCEL
LYEL
PTGX
Return on Assets (Normalized)
5.63%−13.46%−39.52%
Return on Equity (Normalized)
8.24%−15.38%−44.15%
Return on Invested Capital (Normalized)
5.22%−16.60%−48.64%
Return on Assets
VCEL
LYEL
PTGX
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRTtlv$550.2 Bil
VRTX
Vertex Pharmaceuticals IncYdkxyv$111.1 Bil
REGN
Regeneron Pharmaceuticals IncGfsbhw$107.7 Bil
MRNA
Moderna IncYdvz$36.9 Bil
ARGX
argenx SE ADRMymzs$24.2 Bil
BNTX
BioNTech SE ADRYnsb$22.3 Bil
ALNY
Alnylam Pharmaceuticals IncRwprvk$19.9 Bil
BMRN
Biomarin Pharmaceutical IncNzldrpy$17.2 Bil
RPRX
Royalty Pharma PLC Class AYxxpx$13.9 Bil
INCY
Incyte CorpQcgdf$13.6 Bil

Sponsor Center